The AI Drug Development collaboration brings together Harbour BioMed’s Harbour Mice® antibody discovery platform and Evinova’s AI-driven clinical solutions. The partnership aims to shorten drug development timelines, reduce costs, and improve clinical trial efficiency through integrated computational and biologics expertise.
Dr. Jingsong Wang of Harbour BioMed highlighted the impact of the AI Drug Development partnership, stating that AI will be key to improving clinical outcomes and delivering breakthrough therapies to patients faster, globally.
Harbour BioMed contributes its advanced antibody discovery platforms to the AI Drug Development partnership, including H2L2 fully human antibodies and its HCAb heavy-chain-only format. Its HBICE® bispecific technology and HBICA™ immune-modulating platform enable therapeutic possibilities beyond traditional drug combination approaches.
Strengthening its AI Drug Development capabilities, Harbour BioMed recently launched the industry’s first fully human generative AI HCAb model. The model is designed to fast-track biologics discovery and enhance prediction accuracy across the drug R&D pipeline.
Evinova China’s General Manager, Nate Zhang, reiterated the value of the AI Drug Development collaboration, stating that pairing global AI clinical intelligence with China-rooted innovation can accelerate world-class therapies from lab discovery to global markets.
The AI Drug Development strategy mirrors a growing industry shift toward ecosystem-based R&D, where companies combine specialized strengths instead of building end-to-end solutions in isolation. This model supports faster innovation, regulatory alignment, and smarter clinical execution.
Harbour BioMed’s expanding pipeline offers multiple testing grounds for AI Drug Development, particularly in oncology and immunology, areas with high unmet medical need where AI can significantly improve target discovery and clinical predictability.
Announced at CIIE, the AI Drug Development partnership marks China’s advancing role in next-gen drug innovation. The companies plan to build an open collaborator ecosystem, potentially onboarding CROs, hospitals, research labs, and regulatory AI partners.
The long-term impact of the AI Drug Development alliance will be measured by real-world outcomes: faster trials, improved patient enrollment, better efficacy prediction, optimized safety profiling, and accelerated regulatory approvals for life-changing biologics.
Discover how artificial intelligence is revolutionizing pharmaceutical research and accelerating therapeutic breakthroughs, visit ainewstoday.org for comprehensive coverage of AI drug discovery platforms, biopharmaceutical partnerships, clinical development innovations, and the computational technologies transforming how humanity develops life-saving medicines!
